Moon Ho Son

Summary

Affiliation: Research Laboratories
Country: Korea

Publications

  1. ncbi The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes
    Ho Sang Moon
    Research Center, Dong A Pharm Co, Ltd, Yongin 446 905, Korea
    Arch Pharm Res 34:1041-3. 2011
  2. ncbi Dipeptidyl peptidase-4 inhibitor with β-amino amide scaffold: synthesis, SAR and biological evaluation
    Heung Jae Kim
    Dong A Pharm Co, Ltd, 47 5, Sanggal dong, Giheung gu, Yongin si, Gyeonggi do 446 905, Republic of Korea
    Bioorg Med Chem Lett 22:5545-9. 2012
  3. ncbi PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo
    Mi Kyung Kim
    Research Center, Dong A Pharm Co, Ltd, Sanggal dong, Giheung gu, Yongin si, Gyeonggi Do, Republic of Korea
    Eur J Pharmacol 595:119-25. 2008

Collaborators

  • Mi Kyung Kim
  • Heung Jae Kim
  • Ho Sang Moon
  • Jong Pil Min
  • Si Young Sung
  • Hae Sun Kim
  • Soon Hoe Kim
  • Kyung Jin Park
  • Bong Jin Lee
  • Woo Young Kwak
  • Ha Dong Kim

Detail Information

Publications3

  1. ncbi The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes
    Ho Sang Moon
    Research Center, Dong A Pharm Co, Ltd, Yongin 446 905, Korea
    Arch Pharm Res 34:1041-3. 2011
    ..In this report, the authors provide a review on the development of non-peptide GLP-1 receptor agonists and introduce a novel agonist DA-15864...
  2. ncbi Dipeptidyl peptidase-4 inhibitor with β-amino amide scaffold: synthesis, SAR and biological evaluation
    Heung Jae Kim
    Dong A Pharm Co, Ltd, 47 5, Sanggal dong, Giheung gu, Yongin si, Gyeonggi do 446 905, Republic of Korea
    Bioorg Med Chem Lett 22:5545-9. 2012
    ..Several series of β-amino amide containing piperazine derivatives have been prepared and evaluated as a inhibitor of DPP4. Finally compound 5m was selected for further evaluation...
  3. ncbi PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo
    Mi Kyung Kim
    Research Center, Dong A Pharm Co, Ltd, Sanggal dong, Giheung gu, Yongin si, Gyeonggi Do, Republic of Korea
    Eur J Pharmacol 595:119-25. 2008
    ..And its balanced activities may render PAR-5359 as a pharmacological tool in elucidating the complex roles of PPARalpha/gamma dual agonists...